BridgeBio Pharma Long Term Debt 2018-2026 | BBIO
BridgeBio Pharma long term debt from 2018 to 2026. Long term debt can be defined as the sum of all long term debt fields.
- BridgeBio Pharma long term debt for the quarter ending June 30, 2026 was $1.928B, a 4.22% increase year-over-year.
- BridgeBio Pharma long term debt for 2025 was $1.852B, a 7.62% increase from 2024.
- BridgeBio Pharma long term debt for 2024 was $1.721B, a 0.31% decline from 2023.
- BridgeBio Pharma long term debt for 2023 was $1.727B, a 1.12% increase from 2022.
|
BridgeBio Pharma Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2025 | $1,852 |
| 2024 | $1,721 |
| 2023 | $1,727 |
| 2022 | $1,708 |
| 2021 | $1,704 |
| 2020 | $476 |
| 2019 | $92 |
| 2018 | $55 |
|
BridgeBio Pharma Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2026-06-30 | $1,928 |
| 2026-03-31 | $1,926 |
| 2025-12-31 | $1,852 |
| 2025-09-30 | $1,851 |
| 2025-06-30 | $1,850 |
| 2025-03-31 | $1,848 |
| 2024-12-31 | $1,721 |
| 2024-09-30 | $1,719 |
| 2024-06-30 | $1,718 |
| 2024-03-31 | $1,716 |
| 2023-12-31 | $1,727 |
| 2023-09-30 | $1,721 |
| 2023-06-30 | $1,719 |
| 2023-03-31 | $1,713 |
| 2022-12-31 | $1,708 |
| 2022-09-30 | $1,699 |
| 2022-06-30 | $1,693 |
| 2022-03-31 | $1,708 |
| 2021-12-31 | $1,704 |
| 2021-09-30 | $1,375 |
| 2021-06-30 | $1,374 |
| 2021-03-31 | $1,361 |
| 2020-12-31 | $476 |
| 2020-09-30 | $472 |
| 2020-06-30 | $467 |
| 2020-03-31 | $461 |
| 2019-12-31 | $92 |
| 2019-09-30 | $75 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $13.352B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |